These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16371812)

  • 1. Rheumatoid arthritis and tuberculosis in the tumor necrosis factor inhibitors era: observations from Brazil.
    da Rocha Castelar Pinheiro G
    J Clin Rheumatol; 2005 Dec; 11(6):344-6. PubMed ID: 16371812
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
    Pressman Lovinger S
    JAMA; 2003 Jun; 289(24):3229-30. PubMed ID: 12824197
    [No Abstract]   [Full Text] [Related]  

  • 3. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Dougados M; Emery P; Gibofsky A; Kavanaugh AF; Keystone EC; Klareskog L; Russell AS; van de Putte LB; Weisman MH
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii2-9. PubMed ID: 14532138
    [No Abstract]   [Full Text] [Related]  

  • 4. Drugs for rheumatoid arthritis.
    Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of rheumatoid arthritis.
    Handa R
    Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active tuberculosis in a patient with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitor.
    Fuchs I; Abu-Shakra M; Gelfer E; Smoliakov A; Ben-Haroch D; Horowitz J; Avnon LS
    Isr Med Assoc J; 2010 Sep; 12(9):579-81. PubMed ID: 21287806
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious complications of biologic agents.
    Martin-Mola E; Balsa A
    Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.
    Patkar NM; Teng GG; Curtis JR; Saag KG
    Curr Opin Rheumatol; 2008 May; 20(3):320-6. PubMed ID: 18388525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.
    Rajakulendran S; Gadsby K; Allen D; O'Reilly S; Deighton C
    Ann Rheum Dis; 2006 Dec; 65(12):1678-9. PubMed ID: 17105865
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary nasal tuberculosis during anti-tumour necrosis factor alpha treatment of a patient with rheumatoid arthritis.
    Ribeiro S; Ferreira B; Duarte R; Almeida I; Vasconcelos C
    Scand J Infect Dis; 2013 Dec; 45(12):957-60. PubMed ID: 23957541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [TNF-alpha blockers, rheumatoid arthritis and pulmonary tuberculosis].
    Mihăltan F
    Pneumologia; 2007; 56(4):212-6. PubMed ID: 18320798
    [No Abstract]   [Full Text] [Related]  

  • 15. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Emery P; Keystone EC; Schiff MH; van Riel PL; Weinblatt ME; Weisman MH
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii2-15. PubMed ID: 17038465
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 19. When is switching warranted among biologic therapies in rheumatoid arthritis?
    Reynolds A; Koenig AS; Bananis E; Singh A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.